Arcanobacterium

From Wikipedia, the free encyclopedia

Arcanobacterium haemolyticum initially named C. haemolyticum, was first described by MacClean et al. in 1946 from subjects suffering from sore throat. Controversies regarding classification were solved in 1982 when a new genus, Arcanobacterium (enigmatic bacterium) was created based on its peptidoglycan, fatty acid, and DNA characteristics, Since its initial description, the spectrum of diseases caused by A. haemolyticum has been expanded to include sepsis and osteomyelitis. Organisms are Gram-positive, facultative anaerobic, catalase negative rods (but transition to the coccal shape occurs as the organism grows) with arrangements described as matchbox or Chinese letters arrangements. Growth is enhanced in blood and by CO2. Hemolysis is detected on human blood agar plates, and routine plating of specimens suspected of containing A. haemolyticum on human blood agar is suggested to distinguish it from Streptococcus pyogenes (haemolytic on sheep blood). Pitting of the agar below the colonies also helps in identification. A. haemolyticum infection is most common in 15- to 25-year-old persons and manifests as exudative pharyngitis and/or tonsillitis accompanied by cervical lymphadenopathy.^1,2 Symptoms look like those of ß-hemolytic streptococci or viral infection. A rash of the chest and of the abdomen, neck, or extremities is seen in 20% to 25% of cases enhancing the risk of diagnostic error as streptococcal infection or penicillin allergy, when ß-lactam therapy is initiated without exact diagnosis.[1] A. haemolyticum often occurs in polymicrobic infections together with typical respiratory pathogens such as streptococci. The isolation of classical pathogens from specimens that also contain A. haemolyticum might be in part responsible for the tendency to miss the organism. Little is known about the means by which A. haemolyticum causes infection or the associated skin manifestations. The organism is known to produce uncharacterized hemolytic agent(s), a neuraminidase and a phospholipase D (PLD) acting preferentially on sphingomyelin. PLD is known to result in tissue damage, but the role in disease of the cytotoxic effect caused by this extracellular toxin is not established. A. haemolyticum isolated from humans is susceptible to erythromycin (proposed as the first line drug ), clindamycin, gentamicin, and cephalosporins. The use of parenteral antimicrobial drugs must be limited to serious infections.

[edit] References

1. Regina Linder. Rhodococcus equi and Arcanobacterium haemolyticum: Two "Coryneform" Bacteria Increasingly Recognized as Agents of Human Infection Emerging Infectious Diseases. National Center for Infectious Diseases, CDC Atlanta, GA.
2. Kyle Horner, MD, Arcanobacterium haemolyticum e-medicine February 1, 2007

This Tree of Life article needs to be cleaned up to conform to a higher standard of quality. This may include adding a taxonomy box or adding correct categorization, as well as any other cleaning up.
See Wikipedia:How to edit a page and Category:Wikipedia help for help, or this article's talk page.

This bacteria-related article is a stub. You can help Wikipedia by expanding it.